Literature DB >> 20496256

PI3K pathway-directed therapeutic strategies in cancer.

Roshan Agarwal1, Mark Carey, Bryan Hennessy, Gordon B Mills.   

Abstract

PI3K pathway signaling is the focus of intensive oncology drug-development programs at several academic institutions and pharmaceutical companies. With several drugs that target different parts of the pathway in early clinical trials, this review presents evidence demonstrating that the PI3K pathway represents a suitable target for cancer drug development, discusses therapeuticstrategies for targeting the pathway, and highlights the status of drugs currently in development.

Entities:  

Mesh：

Substances：

Year:  2010        PMID： 20496256

Source DB:  PubMed          Journal:  Curr Opin Investig Drugs        ISSN： 1472-4472


  25 in total

1.  PI3K pathway mutations and PTEN levels in primary and metastatic breast cancer.

Authors:  Ana M Gonzalez-Angulo; Jaime Ferrer-Lozano; Katherine Stemke-Hale; Aysegul Sahin; Shuying Liu; Juan A Barrera; Octavio Burgues; Ana M Lluch; Huiqin Chen; Gabriel N Hortobagyi; Gordon B Mills; Funda Meric-Bernstam
Journal:  Mol Cancer Ther       Date:  2011-04-13       Impact factor: 6.261

Review 2.  Targeting the PI3-kinase/Akt/mTOR signaling pathway.

Authors:  Burhan Hassan; Argun Akcakanat; Ashley M Holder; Funda Meric-Bernstam
Journal:  Surg Oncol Clin N Am       Date:  2013-08-06       Impact factor: 3.495

3.  No significant association between PIK3CA mutation and survival of esophageal squamous cell carcinoma: A meta-analysis.

Authors:  Xiao-Qing Ge; Yan-Zheng Yang; Sha-Sha Li; Lu Hou; Jing-Li Ren; Kun-Peng Yang; Xian-En Fa
Journal:  J Huazhong Univ Sci Technolog Med Sci       Date:  2017-06-06

4.  Frequency of mesenchymal-epithelial transition factor gene (MET) and the catalytic subunit of phosphoinositide-3-kinase (PIK3CA) copy number elevation and correlation with outcome in patients with early stage breast cancer.

Authors:  Ana M Gonzalez-Angulo; Huiqin Chen; Meghan S Karuturi; Mariana Chavez-MacGregor; Spyrus Tsavachidis; Funda Meric-Bernstam; Kim-Anh Do; Gabriel N Hortobagyi; Patricia A Thompson; Gordon B Mills; Melissa L Bondy; George R Blumenschein
Journal:  Cancer       Date:  2012-06-26       Impact factor: 6.860

5.  Selective inhibition of phosphoinositide 3-kinase p110α preserves lymphocyte function.

Authors:  Lomon So; Sung Su Yea; Jean S Oak; Mengrou Lu; Arun Manmadhan; Qiao Han Ke; Matthew R Janes; Linda V Kessler; Jeff M Kucharski; Lian-Sheng Li; Michael B Martin; Pingda Ren; Katti A Jessen; Yi Liu; Christian Rommel; David A Fruman
Journal:  J Biol Chem       Date:  2012-12-28       Impact factor: 5.157

Review 6.  PI3K and cancer: lessons, challenges and opportunities.

Authors:  David A Fruman; Christian Rommel
Journal:  Nat Rev Drug Discov       Date:  2014-02       Impact factor: 84.694

7.  Inhibition of the α-Subunit of Phosphoinositide 3-Kinase in Heart Increases Late Sodium Current and Is Arrhythmogenic.

Authors:  Tao Yang; David F Meoli; Javid Moslehi; Dan M Roden
Journal:  J Pharmacol Exp Ther       Date:  2018-03-21       Impact factor: 4.030

Review 8.  Circulating tumor cells and epithelial, mesenchymal and stemness markers: characterization of cell subpopulations.

Authors:  Guislaine Barriere; Pietro Fici; Giulia Gallerani; Francesco Fabbri; Wainer Zoli; Michel Rigaud
Journal:  Ann Transl Med       Date:  2014-11

9.  Defining biomarkers to predict sensitivity to PI3K/Akt/mTOR pathway inhibitors in breast cancer.

Authors:  A M Gonzalez-Angulo; G R Blumenschein
Journal:  Cancer Treat Rev       Date:  2012-12-06       Impact factor: 12.111

Review 10.  Targeting therapeutic liabilities engendered by PIK3R1 mutations for cancer treatment.

Authors:  Lydia Wt Cheung; Gordon B Mills
Journal:  Pharmacogenomics       Date:  2016-01-25       Impact factor: 2.533
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.